SAB BIOTHERAPEUTICS, INC. Finance Lease, Right-of-Use Asset, Amortization
SAB BIOTHERAPEUTICS, INC. (SABS) reported Finance Lease, Right-of-Use Asset, Amortization of $22.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:FinanceLeaseRightOfUseAssetAmortization · last filed 2026-08-06
- SAB BIOTHERAPEUTICS, INC. finance lease, right-of-use asset, amortization for the quarter ending 2026-06-30 was $22.00K, a 0.00% change year-over-year.
- SAB BIOTHERAPEUTICS, INC. finance lease, right-of-use asset, amortization for the quarter ending 2026-03-31 was $21.70K, a 0.00% decline year-over-year.
- SAB BIOTHERAPEUTICS, INC. finance lease, right-of-use asset, amortization for the quarter ending 2025-12-31 was $21.71K, a 0.00% change year-over-year.
- SAB BIOTHERAPEUTICS, INC. finance lease, right-of-use asset, amortization for the quarter ending 2025-09-30 was $22.00K, a 0.00% change year-over-year.
- SAB BIOTHERAPEUTICS, INC. finance lease, right-of-use asset, amortization for fiscal 2025 was $86.82K, a 0.00% decline from fiscal 2024.
- SAB BIOTHERAPEUTICS, INC. finance lease, right-of-use asset, amortization for fiscal 2024 was $86.82K, a 5.76% decline from fiscal 2023.
- SAB BIOTHERAPEUTICS, INC. finance lease, right-of-use asset, amortization for fiscal 2023 was $92.13K, a 24.76% decline from fiscal 2022.
- SAB BIOTHERAPEUTICS, INC. finance lease, right-of-use asset, amortization for fiscal 2022 was $122.45K, a 25.79% decline from fiscal 2021.
| Period end | Finance Lease, Right-of-Use Asset, Amortization 3 month | Finance Lease, Right-of-Use Asset, Amortization 3 month as first filed | Finance Lease, Right-of-Use Asset, Amortization 6 month | Finance Lease, Right-of-Use Asset, Amortization 6 month as first filed | Finance Lease, Right-of-Use Asset, Amortization 9 month | Finance Lease, Right-of-Use Asset, Amortization 9 month as first filed | Finance Lease, Right-of-Use Asset, Amortization 12 month | Finance Lease, Right-of-Use Asset, Amortization 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $22.00K 10-Q · filed 2026-08-06 | $43.00K 10-Q · filed 2026-08-06 | $65.41K derived: sum of 3 quarters · filed 2026-08-06 | $87.41K derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | $21.70K 10-Q · filed 2026-05-12 | $43.41K derived: sum of 2 quarters · filed 2026-05-12 | $65.41K derived: sum of 3 quarters · filed 2026-05-12 | $87.41K derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-12-31 | $21.71K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $43.71K derived: sum of 2 quarters · filed 2026-03-09 | $65.71K derived: sum of 3 quarters · filed 2026-08-06 | $86.82K 10-K · filed 2026-03-09 | ||||
| 2025-09-30 | $22.00K 10-Q · filed 2025-11-14 | $44.00K derived: sum of 2 quarters · filed 2026-08-06 | $65.12K 10-Q · filed 2025-11-14 | $87.41K derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | $22.00K 10-Q · filed 2026-08-06 | $43.00K 10-Q · filed 2026-08-06 | $43.41K 10-Q · filed 2025-08-07 | $65.41K derived: sum of 3 quarters · filed 2026-08-06 | $87.41K derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-03-31 | $21.71K 10-Q · filed 2026-05-12 | $43.41K derived: sum of 2 quarters · filed 2026-05-12 | $65.41K derived: sum of 3 quarters · filed 2026-05-12 | $87.41K derived: sum of 4 quarters · filed 2026-05-12 | ||||
| 2024-12-31 | $21.71K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $43.71K derived: sum of 2 quarters · filed 2026-03-09 | $65.71K derived: sum of 3 quarters · filed 2026-03-09 | $86.82K 10-K · filed 2026-03-09 | ||||
| 2024-09-30 | $22.00K 10-Q · filed 2025-11-14 | $44.00K derived: sum of 2 quarters · filed 2025-11-14 | $65.12K 10-Q · filed 2025-11-14 | $87.62K derived: sum of 4 quarters · filed 2025-11-14 | ||||
| 2024-06-30 | $22.00K 10-Q · filed 2025-08-07 | $43.41K 10-Q · filed 2025-08-07 | $65.62K derived: sum of 3 quarters · filed 2025-08-07 | $87.62K derived: sum of 4 quarters · filed 2025-08-07 | ||||
| 2024-03-31 | $21.71K 10-Q · filed 2025-05-09 | $43.62K derived: sum of 2 quarters · filed 2025-05-09 | $65.62K derived: sum of 3 quarters · filed 2025-05-09 | $88.62K derived: sum of 4 quarters · filed 2025-05-09 | ||||
| 2023-12-31 | $21.91K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $43.91K derived: sum of 2 quarters · filed 2025-03-31 | $66.91K derived: sum of 3 quarters · filed 2025-03-31 | $92.13K 10-K · filed 2025-03-31 | ||||
| 2023-09-30 | $22.00K 10-Q · filed 2024-11-06 | $45.00K derived: sum of 2 quarters · filed 2024-11-06 | $70.22K 10-Q · filed 2024-11-06 | $70.00K 10-Q · filed 2023-11-13 | $94.17K derived: sum of 4 quarters · filed 2024-11-06 | |||
| 2023-06-30 | $23.00K 10-Q · filed 2024-08-08 | $48.21K 10-Q · filed 2024-08-08 | $48.00K 10-Q · filed 2023-08-21 | $72.17K derived: sum of 3 quarters · filed 2024-08-08 | $97.17K derived: sum of 4 quarters · filed 2024-08-08 | |||
| 2023-03-31 | $24.72K 10-Q · filed 2024-05-20 | $25.00K 10-Q · filed 2023-05-15 | $49.16K derived: sum of 2 quarters · filed 2024-05-20 | $74.17K derived: sum of 3 quarters · filed 2024-05-20 | $106.17K derived: sum of 4 quarters · filed 2024-05-20 | |||
| 2022-12-31 | $24.45K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $49.45K derived: sum of 2 quarters · filed 2024-03-29 | $81.45K derived: sum of 3 quarters · filed 2024-03-29 | $122.45K 10-K · filed 2024-03-29 | $122.00K 10-K · filed 2023-04-14 | |||
| 2022-09-30 | $25.00K 10-Q · filed 2023-11-13 | $57.00K derived: sum of 2 quarters · filed 2023-11-13 | $98.00K 10-Q · filed 2023-11-13 | $139.00K derived: sum of 4 quarters · filed 2023-11-13 | ||||
| 2022-06-30 | $32.00K 10-Q · filed 2023-08-21 | $73.00K 10-Q · filed 2023-08-21 | $114.00K derived: sum of 3 quarters · filed 2023-08-21 | $155.00K derived: sum of 4 quarters · filed 2023-08-21 | ||||
| 2022-03-31 | $41.00K 10-Q · filed 2023-05-15 | $82.00K derived: sum of 2 quarters · filed 2023-05-15 | $123.00K derived: sum of 3 quarters · filed 2023-05-15 | $164.00K derived: sum of 4 quarters · filed 2023-05-15 | ||||
| 2021-12-31 | $41.00K derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-04-28 | $82.00K derived: sum of 2 quarters · filed 2023-04-28 | $123.00K derived: sum of 3 quarters · filed 2023-04-28 | $165.00K 10-K/A · filed 2023-04-28 | ||||
| 2021-09-30 | $41.00K 10-Q · filed 2022-11-14 | $82.00K derived: sum of 2 quarters · filed 2022-11-14 | $124.00K 10-Q · filed 2022-11-14 | |||||
| 2021-06-30 | $41.00K 10-Q · filed 2022-08-10 | $82.00K 10-Q · filed 2022-08-10 | ||||||
| 2021-03-31 | $41.00K 10-Q · filed 2022-05-12 | |||||||
| 2020-12-31 | $165.00K 10-K/A · filed 2023-04-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |